CD39 Blocking Peptide is synthetically produced from the 440-490 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20ยฐC for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide taken within amino acid region 440-490 on human EctoNucleoside TriPhosphate Diphosphohydrolase 1.
Immunogen Region
440-490
Additional Info
Tissue Specificity
Expressed primarily on activated lymphoid cells. Also expressed in endothelial tissues. Highly expressed in placenta, lung, skeletal muscle, kidney.
Post Translational Modifications
N-glycosylated. The N-terminus is blocked. Palmitoylated on Cys-13.which is required for caveola targeting.
Function
Catalyzes the hydrolysis of both di- and triphosphate nucleotides (NDPs and NTPs) and hydrolyze NTPs to nucleotide monophosphates (NMPs) in two distinct successive phosphate-releasing steps, with NDPs as intermediates and participates in the regulation of extracellular levels of nucleotides (Probable). By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, it blocks platelet aggregation and supports blood flow.
